Labcorp Holdings Inc (NYSE:LH) disclosed an insider sale and related share movements by its Executive Vice President, Operations, Jonathan C. Meltzer, in filings with the Securities and Exchange Commission.
On March 27, 2026, Meltzer sold 839 shares of Labcorp common stock at a price of $267.05 per share, yielding proceeds of $224,054. That sale price was marginally above the contemporaneous stock price of $266.84.
The Form 4 filing also records that Meltzer acquired 2,388 shares of Labcorp common stock on March 26, 2026, in connection with a performance award. In relation to that award, 711 shares were withheld to satisfy tax withholding obligations at a price of $268.38 per share, for a withheld value totaling $190,818.
After accounting for the March transactions, Meltzer directly holds 3,620.3256 shares of Labcorp Holdings Inc.
Separately, the company released its fourth-quarter 2025 financial results. Labcorp reported adjusted earnings per share of $4.07, exceeding the consensus estimate of $3.93. Revenue for the quarter was $3.52 billion, missing the anticipated $3.56 billion.
In operational developments, Labcorp said it will expand a collaboration with PathAI to roll out the AISight Dx digital pathology platform across its anatomic pathology laboratories and hospital partnerships. The company described the platform as FDA-cleared and said it will improve digital handling of slides and support diagnostic workflows through artificial intelligence.
On the leadership front, the filing notes that Labcorp’s former Executive Vice President and Chief Financial Officer, Glenn Eisenberg, has taken a seat on the board of directors at The Middleby Corporation. Eisenberg retired from Labcorp in December 2024 and remains with the company as a Special Advisor.
The stock has returned 16% over the past year, and analysts cited in the filing project roughly 12% upside potential. These various items - insider transactions, quarterly results, a strategic technology collaboration, and an executive board appointment - were included in regulatory filings and company disclosures related to the period.
The information above is drawn from the company’s regulatory filings and corporate announcements.